One of the most common long-term worries in the GLP-1 community goes something like this: if you keep stimulating the GLP-1 receptor week after week, won't it eventually "burn out"? People mean a few different things by it — that the drug will stop working, that you'll need endless dose increases, or that you'll permanently damage your body's own appetite system and be worse off than before you started.
It's a reasonable question, and it isn't pulled from nowhere. But the long-term evidence tells a much more reassuring story than the word "burnout" suggests.
Where the idea comes from
The fear has a kernel of real biology. The GLP-1 receptor is a G-protein-coupled receptor, and that family of receptors can desensitize — dial down their response — when they're stimulated continuously. That's a genuine cellular phenomenon studied in pharmacology.
But "receptors can desensitize at the cellular level" is not the same as "the treatment burns out and quits," and the leap between those two is where the myth lives. Whether a drug keeps working over months and years is a question you answer with long-term clinical data, not with a cell-biology analogy.
What the long-term trials actually show
Here's the key evidence. In the STEP 5 trial, adults taking semaglutide for two years lost about 15% of their body weight and kept it off, versus about 2.6% with placebo — substantial, sustained weight loss maintained across the full 104 weeks. The effect didn't erode away as though the receptors were wearing out.
That's the opposite of what "burnout" would predict. With continued treatment, the medication keeps doing its job.
Then why do I plateau?
Because a plateau isn't burnout. Weight loss slows and stops for almost everyone, and the reason is a new equilibrium, not a failing receptor: as you get smaller, your body needs fewer calories, so the same intake that once produced a deficit eventually matches your new energy needs. The medication is still working — it's holding your appetite down at a lower body weight. (Our guide on what to realistically expect on a GLP-1 covers the plateau in detail, and how the medications work explains the receptor side.)